EUR/USD likely to find a peak near 1.25: UBS
HONG KONG, SHANGHAI, FLORHAM PARK, NJ - HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) disclosed that its Executive Director, Chief Executive Officer, and Chief Scientific Officer, Dr. Weiguo Su, has been granted 19,913 ordinary shares under the company’s Long Term Incentive Plan (LTIP), which vested on Thursday. The shares were awarded on March 13, 2024, and vested a year later, as per the conditions of the LTIP.
The LTIP is designed to incentivize key employees and align their interests with those of shareholders. The transaction took place outside a trading venue, with the shares granted at no cost to Dr. Su. This vesting event is part of HUTCHMED’s ongoing efforts to reward and retain its senior management team.
HUTCHMED is a biopharmaceutical company that specializes in developing targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has successfully marketed three medicines in China, with one also approved in the United States, Europe, and Japan. The company’s commitment to innovation and global development has been a cornerstone of its strategy since its inception.
The transaction was reported in accordance with the UK Market Abuse Regulation, ensuring transparency in the dealings of the company’s management. The details of the transaction, including the name of the award holder and the number of shares vested, have been made public following regulatory requirements.
This information is based on a press release statement from HUTCHMED. The company continues to focus on bringing new drug candidates from its in-house discovery team to patients worldwide, emphasizing its role in the international pharmaceutical landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.